These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17909371)

  • 1. Methodologic challenges to studying patient safety and comparative effectiveness.
    Strom BL
    Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 3. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 4. Research challenges: overview of epidemiological study designs.
    Bombardier C
    J Rheumatol Suppl; 1988 Oct; 17():5-8. PubMed ID: 3204620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pharmacoepidemiology research in postmarketing surveillance and anesthesia practice/critical care medicine.
    Grasela TH; Watkins WD; Hug CC; McLeskey CH; Nahrwold ML; Roizen MF; Stanley TH; Thisted RA; Walawander CA; White PF
    Anesth Analg; 1993 Oct; 77(4 Suppl):S44-50. PubMed ID: 8214697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design considerations in an active medical product safety monitoring system.
    Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of different logistical approaches to postmarketing surveillance.
    Strom BL
    J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
    Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological considerations in observational comparative effectiveness research for implantable medical devices: an epidemiologic perspective.
    Jalbert JJ; Ritchey ME; Mi X; Chen CY; Hammill BG; Curtis LH; Setoguchi S
    Am J Epidemiol; 2014 Nov; 180(9):949-58. PubMed ID: 25255810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
    Czeizel AE
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):635-9. PubMed ID: 11980253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
    Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology: theory, study design, and planning for education.
    Harris SA
    J Contin Educ Health Prof; 2000; 20(3):133-45. PubMed ID: 11232249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symmetry analysis for monitoring safety of newly marketed drugs.
    Kubota K
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bias.
    Delgado-Rodríguez M; Llorca J
    J Epidemiol Community Health; 2004 Aug; 58(8):635-41. PubMed ID: 15252064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A framework for evidence evaluation and methodological issues in implantable device studies.
    Sedrakyan A; Marinac-Dabic D; Normand SL; Mushlin A; Gross T
    Med Care; 2010 Jun; 48(6 Suppl):S121-8. PubMed ID: 20421824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
    Faden LB; Milne CP
    Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.